Can Shorter TB Prevention Regimens Work?
Randomized study evaluates efficacy, safety, and completion in high-risk patients
-
By
-
Julia Cipriano, MS, CMPP
-
March 23, 2026
-
Clinical Scorecard: Can Shorter TB Prevention Regimens Work?
At a Glance
| Category | Detail |
|---|
| Condition | Tuberculosis (TB) prevention in patients with rheumatic diseases |
| Key Mechanisms | Modified 3-month rifapentine plus isoniazid regimen |
| Target Population | Patients aged 18 to 70 years with high-risk rheumatic diseases and latent TB infection |
| Care Setting | Tertiary general hospitals |
Key Highlights
- 3-month rifapentine plus isoniazid (3HP) regimen showed noninferiority to standard 9-month isoniazid (9H) regimen
- Cumulative TB rate was 0% in 3HP group vs 1.2% in 9H group
- Adverse drug reactions were lower in 3HP group (9.6%) compared to 9H group (15%)
- Treatment completion rates were similar: 89.6% for 3HP vs 91.2% for 9H
- Study provides high-level evidence for a viable alternative TB prevention regimen
Guideline-Based Recommendations
Diagnosis
- Consider screening for latent TB in patients with rheumatic diseases on immunosuppressive therapy
Management
- Consider 3-month rifapentine plus isoniazid regimen as an alternative to the standard 9-month regimen
Monitoring & Follow-up
- Monitor for adverse drug reactions and hepatotoxicity during treatment
Risks
- Potential for lower event rates and limited generalizability beyond high-risk populations
Patient & Prescribing Data
Patients with rheumatic diseases receiving immunosuppressive therapy
Short-course regimens may reduce treatment burden and drug toxicity
Clinical Best Practices
- Encourage treatment adherence through patient education on the benefits of shorter regimens
- Evaluate patient comorbidities and concomitant medications before prescribing
- Consider the impact of the COVID-19 pandemic on TB exposure and reporting
References
